Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Kath Kerry

- PMLiVE

MHRA grants bluebird bio’s LentiGlobin gene therapy an ‘innovation passport’

The Innovative Licensing and Access Pathway scheme aims to help speed approval of innovative treatments

- PMLiVE

Moderna says its COVID-19 vaccine appears effective against Delta and other variants

Earlier this year, the company revealed early evidence that its booster jabs may be effective against ‘variants of concern’

- PMLiVE

EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy

The five therapeutic candidates include a repurposed arthritis med and monoclonal antibodies

- PMLiVE

Pardes Biosciences, backed by Gilead and Foresite, goes public to advance lead COVID-19 antiviral drug

Pardes’ lead oral antiviral drug candidate is designed to inhibit the main protease of SARS-CoV-2

- PMLiVE

Maintaining employee engagement and morale in a hybrid workspace

by Ondine Whittington

- PMLiVE

The power of the patient influencer

by Lorraine Walters

- PMLiVE

Stick or twist? The future of HCP engagement

The Covid-19 pandemic forced companies to be more agile and rethink their value offering when engaging with HCPs, but what does the future of HCP engagement look like?

Say Communications

Sanofi reception

Sanofi to invest €400m annually in mRNA vaccines facility

French pharma company will build end-to-end R&D of ‘next-generation’ mRNA vaccines

- PMLiVE

Healthcare tech: the driving force behind value-based care?

In 2020, healthcare technology investment went into overdrive. We speak to Sunny Kumar, Partner at GSR Ventures, to find out how COVID‑19 has transformed the industry and whether healthcare technology...

Avalere Health

- PMLiVE

Anavex’s CNS drug slows progression of motor and non-motor symptoms in Parkinson’s disease

Clinical benefit correlated with increase in target biomarker SIGMAR1

- PMLiVE

Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study

New results follow success of BMS’ Breyanzi in the same patient population and setting

- PMLiVE

Study finds mixed vaccine schedules provide strong immune response against COVID-19

And AZ's Vaxzevria COVID-19 vaccine shows strong immune responses following a delayed second dose

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links